To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

The hourlong program "Why Can't We Cure Cancer? A National Conversation" comes as a follow-up to NewsNation's November ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients.

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

Regimen significantly improved survival over standard neoadjuvant chemotherapy ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...